Neuren Pharmaceuticals(ASX:NEU)
Developing drug therapies forserious neurological disorders that emerge in early childhood &have no or limited treatment options
Highly successful US launchof DAYBUE™ (trofinetide) for Rett syndrome by partner Acadia
2023 net sales of US$177.2m;A$27m NEU royalties
1Q24 net sales US$75.9;A$11.6m royalties
2024 net sales guidance ofUS$370-420m; would earn NEU A$61-70m + A$77m sales milestone
Acadia advancingDAYBUE™ in Canada, Europe & Japan
NNZ-2591 in Phase 2 trialsfor four syndromes; 5x Rett market
All indications received FDAinvestigational new drug (IND) & orphan drug designation
Pitt Hopkins topline resultsexpected 2Q24, Angelman results expected 3Q24
Dec'23: PMS demonstratedsignificantly positive results, preparation underway for FDA end of Ph2 meeting
$243.1m cash as of 31 Mar'24
Market cap ~ $2.58B
- Forums
- ASX - By Stock
- Neuren Media and Analyst Coverage
Neuren Pharmaceuticals(ASX:NEU)Developing drug therapies...
-
- There are more pages in this discussion • 160 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.00 |
Change
0.090(0.45%) |
Mkt cap ! $2.556B |
Open | High | Low | Value | Volume |
$19.88 | $20.07 | $19.73 | $11.80M | 591.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 5901 | $19.97 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.00 | 3262 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2035 | 19.830 |
5 | 3099 | 19.810 |
3 | 2596 | 19.800 |
1 | 866 | 19.790 |
1 | 3096 | 19.780 |
Price($) | Vol. | No. |
---|---|---|
20.000 | 1036 | 3 |
20.020 | 2119 | 3 |
20.050 | 2151 | 2 |
20.060 | 1000 | 2 |
20.070 | 1145 | 1 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online